Nephrology

Resource Center

From the Journal

Nephrology

Ascending Paralysis, Hyperkalemia, and Acute Renal Failure in an Older Woman

11/10/2009

Gema Muñoz, MD; José Vives, MD; Baltasar Sánchez, MD; Mónica Rodríguez, MD, PhD; Javier Garau, MD, PhD

Acute ascending paralysis secondary to hyperkalemia is a serious but reversible medical emergency.

11/10/2009

Consultant360 Section Editor in Nephrology:

James Matera, DO

James Matera, DO, is the Consultant360 Section Editor in Nephrology, a practicing nephrologist, Senior Vice President for Medical Affairs, and Chief Medical Officer at CentraState Medical Center (Freehold, New Jersey).

Research Summaries

Research Summary

Research Summary

Firsekibart Outperforms Colchicine for Preventing Gout Flares During Urate-Lowering Therapy

12/22/2025

Ashton L. Stahl

Initiation of urate-lowering therapy (ULT) is frequently complicated by acute gout flares, and the need for safe and effective prophylaxis remains a challenge in clinical practice. A new phase 2 trial from...

12/22/2025

Research Summary

Does Epaminurad Safely and Effectively Lower Serum Urate in Gout?

11/24/2025

Ashton L. Stahl

In a 12-week, multicenter, randomized, double-blind, placebo-controlled phase 2b trial, the selective hURAT1 inhibitor epaminurad produced rapid, dose-dependent reductions in serum urate in adults with...

11/24/2025

Conference Coverage

Conference Coverage

How Do Physicians Prioritize Treatment Attributes When Selecting siRNA Therapy for Primary Hyperoxaluria Type 1?

11/16/2025

Anthony Calabro, MA

In a qualitative study of physicians managing patients with primary hyperoxaluria type 1 (PH1), presented at Kidney Week 2025, clinicians emphasized simplicity, patient convenience, and ease of...

11/16/2025

Research Summary

Shorter-Duration Pegloticase Infusions Safe and Effective in Uncontrolled Gout

10/16/2025

Miranda Manier, BA

In a phase 4 trial, 60-minute pegloticase infusions co-administered with methotrexate demonstrated safety, tolerability, and efficacy comparable to the standard 120-minute duration, with a 67% treatment...

10/16/2025

Research Summary

Research Summary

Urate-Lowering Therapy Does Not Increase Kidney Disease Risk in Patients With Gout

10/09/2025

Kate Young

A recent study examining gout and chronic kidney disease found that achieving a serum urate level below 6 mg/dL with urate-lowering therapy does not increase the risk of severe or end-stage kidney disease...

10/09/2025

April 2026

Current Issue

April 2026